FibroTest Score Test

The FibroTest score estimates the degree of fibrosis, or scarring, in the liver. Fibrosis develops when the liver is repeatedly injured by conditions such as chronic hepatitis B or C, non-alcoholic fatty liver disease (NAFLD), or heavy alcohol use. Over time, healthy liver tissue is replaced by scar tissue, which can progress to cirrhosis, a stage where the liver’s ability to function is severely compromised.

Instead of taking a liver biopsy, which involves inserting a needle into the liver to extract tissue for microscopic examination, the FibroTest combines the results of several standard blood measurements. These include proteins linked to liver function, markers of inflammation, and indicators of bile duct and red blood cell health. Using an algorithm, these results are translated into a score ranging from 0 (no fibrosis) to 1 (advanced fibrosis). The score is then mapped to stages of fibrosis similar to what a biopsy would reveal.

FibroTest has been studied across multiple liver diseases. In hepatitis B and C, it can identify advanced scarring with fairly good accuracy, although false positives and negatives remain possible. In NAFLD, its performance is strongest for cirrhosis but less reliable for early or moderate fibrosis. In alcoholic liver disease, its value is similar to biopsy, though results can be less accurate in patients with coexisting conditions like diabetes or severe obesity.

One limitation is that the FibroTest can be influenced by other medical conditions that alter its component markers. For example, inflammation, hemolysis (the breakdown of red blood cells), or kidney disease can change results without reflecting true liver damage. Laboratory variability can also affect scoring. For these reasons, FibroTest is best interpreted in the context of a patient’s overall clinical picture, and often in combination with imaging studies such as elastography.

Despite its limitations, the FibroTest is a useful tool for reducing unnecessary biopsies, monitoring liver health over time, and identifying individuals at higher risk of progression to cirrhosis or liver-related complications. For patients, it provides a safer, repeatable way to track liver fibrosis without the risks associated with invasive procedures.